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SERUM S-100B AS A POTENTIAL BIOMARKER FOR MENINGITIS IN FEBRILE INFANTS – 
AN INTERIM ANALYSIS.  Kelvin C. Lau, Melissa L. Langhan, and Kirsten A. Bechtel.  Section of 
Emergency Medicine, Department of Pediatrics, Yale University School of Medicine, New Haven, CT. 
The purpose of this study is to identify the utility of serum S-100B levels as a marker for 
meningitis in febrile infants younger than 3 months of age. 
All infants younger than 3 months of age who presented to the Pediatric Emergency Department 
(PED) of  Yale-New Haven Children's Hospital and required both a lumbar puncture and venipuncture due 
to either a confirmed rectal temperature ≥38.0ºC or an overall presentation that concerned the responsible 
physician for possible meningitis and required a lumbar puncture as part of their PED evaluation, were 
prospectively enrolled.  A total of 111 patients participated after a 1.5-year recruitment period or about 
40% of the 260 subjects calculated a priori to be required over 3 years in order to achieve 80% power.  
After informed written consent, approximately 1 mL of blood was obtained for the analysis of the serum 
level of S-100B, in addition to the volume normally drawn for standard laboratory analysis.  Patients with 
confirmed meningitis as defined by a positive viral or bacterial culture, a positive polymerase chain 
reaction (PCR) for enterovirus or herpes simplex virus, and/or cerebrospinal fluid (CSF) pleocytosis, were 
compared with those subjects without meningitis.  S-100B levels for 101 subjects were available for 
interim analysis, of which 27 (26.7%)met the criteria for meningitis and 74 (73.3%) did not.    
 The median S-100B level in infants with meningitis was 247.0 ng/L (95% CI: 103.5, 804), as 
compared to 199.1 ng/L (142.5, 384.0) in those without meningitis (p>0.05).  Receiver operating 
characteristic analysis revealed an area under the curve of 0.4917 (0.3940, 0.5863).  Ad hoc power 
calculations demonstrated a 57% probability of detecting a difference of 390 ng/L between the two groups 
when using this sample size. 
  At this time, this interim analysis of this ongoing study suggests that a larger sample size will still 
be required to determine if serum S-100B is a useful marker for meningitis in febrile young infants.  
Because CSF fluid analysis and the associated risks of lumbar puncture remain the only means by which to 
identify infants with meningitis, the search for a simple serum test for to determine the likelihood of 




 Fever among infants younger than 3 months of age is a common and distressing 
event for caregivers, which often leads to medical evaluation in either primary care 
physician offices or emergency departments.  In this group of young febrile infants, the 
main concern for medical practitioners is the identification of a viral or bacterial source 
for the hyperpyrexia.  Most worrisome of the potential serious infections in this age 
group is meningitis, especially bacterial meningitis.   
 Fortunately, self-limited viral infections have been cited as the most common 
cause of fever in young infants.1 Recent evidence further suggest that particular viral 
agents, such as respiratory syncytial virus (RSV) or influenza A, tend to be the exclusive 
etiology of fever in young infants and subsequently reduce the risk of concomitant 
serious bacterial infection (SBI).2, 3  However, the incidence of viral meningitis, most 
often due to enterovirus, in the group of young febrile infants may still be as high as 13.5 
percent.1 
 SBI, defined as bacteremia, bacterial gastroenteritis, pneumonia, urinary tract 
infection, and meningitis, among febrile infants less than 90 days old has an average 
cumulative incidence of approximately 9 percent in a review of 18 studies from 1977-
1993.4  In turn, cumulative incidence of bacterial meningitis in the same age group was 
around 1.6 percent during this period of study.  Since then, the incidence rate of the 
leading cause of bacterial meningitis in children less than 5 years old, Haemophilus 
influenzae type B, has continued to decline to near elimination due to the inclusion of the 
H. influenza type B conjugate vaccine into the vaccination schedule starting at age 2 
months.5   In spite of the low incidence of SBI in young infants today, a delayed or 
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missed diagnosis of bacterial meningitis may result in dire yet preventable consequences, 
such as subdural empyema, hydrocephalus, cerebral infarction, seizures, and death.6, 7  
Cognitive and executive functioning are also affected for at least a decade after the 
diagnosis, with a more pronounced deficit in children afflicted before 12-months of age.8  
Such persistent sequelae occurs in up to 50 percent of survivors, in spite of advancements 
in treatment.9, 10  Early identification of patients at risk of meningitis, due to either 
bacteria or viruses, is thus imperative. 
The assessment of young febrile infants has kindled passionate debate among 
physicians regarding the management of these patients.11  What alarms physicians is not 
necessarily the ill-appearance of an infant with an obvious source of infection, as a quick 
physical examination in these patients likely would direct diagnostic approach and 
rapidly result in initiation of treatment.  Rather, controversy centers on those infants who 
seemingly appear healthy, but in whom fever raises the possibility of an underlying 
serious illness.  Various prospective studies of infants younger than 90 days old have 
shown that as many as 7% of well-appearing febrile infants may in fact have 
meningitis.12-15  Similarly, fever may be the only dependable clinical manifestation of 
infants with meningitis.6, 7, 16, 17  This is troubling, as the limited, if not virtual absence, of 
social interaction skills necessarily elevates the importance of visual inspection in the 
early assessment of febrile infants younger than 3 months.  Measures developed to 
facilitate the evaluation of these patients, including one well-investigated clinical 
observation scale,18 unfortunately have been undependable when specifically applied to 
either children under 2,13, 19 and especially those 3 months of age.1, 14  Physical 
examination of this young group of infants thus may still be inadequate in the 
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identification of an etiology for fever and may not confidently exclude meningitis and 
other serious illnesses.  Research has thus since focused upon specific clinical and 
laboratory factors, or a combination thereof, that would identify healthy-appearing infants 
at particularly high risk for meningitis or SBI. 
Several protocols for the management of fever in infants less than 3 months of age 
have been published.1, 14, 15  Each of these protocols have excellent negative predictive 
values (94.6-99.7%) and are able to guide practitioners as to which febrile infants are at 
lower risk for SBI.  However, because of their poor positive predictive values (12-14%), 
many infants, may undergo hospitalization and treatment with antibiotics due to 
erroneous classification as being high-risk for SBI.  Although the positive predictive 
value for the Boston criteria was not provided, the authors did provide data that their 
strategy is more cost-effective because their empiric use of antibiotics in both high- and 
low-risk patients led to a lower overall hospital admission rate.20 
Assessment for meningitis and other serious illnesses in young infants is further 
complicated by the fact that the risk of infection appears to be inversely proportional to 
age.  In other words, the younger the infant, the higher the risk of meningitis and SBI.21  
Indeed, prospective application of the Philadelphia criteria to infants 3-28 days old 
resulted in an unacceptable 15.2 percent being misclassified as low-risk for serious 
infections compared to 1.5 percent in the originally studied older (29-56 days) age 
group.19  The Boston protocol is similarly unreliable when the age range is expanded to 
include infants younger than 28 days, as a retrospective application in 225 febrile patients 
less than 1 months old mistakenly identified 25.8 percent with SBI as low-risk.11  Only 
the Rochester protocol is inherently designed for febrile infants under 1 month of age.  
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While only 2 of 227 patients identified as low risk by the Rochester criteria indeed had 
SBI, this analysis was a combination of three separate studies.  Because this study is not 
entirely composed of consecutively eligible infants, many have questioned the validity 
and usefulness of this data.11, 15 
 In addition, the choice of laboratory parameters used to determine risk for 
meningitis and SBI also differs among these three protocols.  Of particular interest is the 
inconsistent use of cerebrospinal fluid (CSF) data, the current gold standard, for the 
diagnosis of meningitis.  The threshold for an abnormal CSF white blood cell count 
(WBC) varies between the Boston and Philadelphia criteria (10 WBC/mm3 versus 8 
WBC/mm3, respectively), while the latter also included a negative CSF Gram stain 
amongst its laboratory parameters.1, 14  Most notably, a lumbar puncture is not included in 
the Rochester criteria.  In a proposal of an alternative predictive model for SBI in young 
febrile infants, Bachur et al. retrospectively applied the Philadelphia and Rochester 
criteria to 5279 infants less than 90 days old, of whom 373 (7%) were diagnosed with 
SBI and 17 specifically identified as bacterial meningitis.12  Because not all measures of 
either criterion were available for every patient, a complete and direct comparison could 
not be made in hindsight.  The results are nonetheless suggestive.  The Rochester criteria 
likely would have misclassified 6 patients with bacterial meningitis and 77 patients 
overall as low-risk for any SBI, while the Philadelphia criteria would have missed 2 
patients with meningitis and 69 patients overall.  The latter is in spite of the Philadelphia 
criteria’s use of a CSF WBC parameter in addition to peripheral WBC count and 
urinalysis (UA).  What is more, the novel decision-making algorithm tested by Bachur et 
al., which consisted of UA, peripheral WBC, temperature, and age, fared only slightly 
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better.  Sixty-six infants were misclassified as low risk for SBI, of whom 11 well- and ill-
appearing patients were bacteremic and grew blood-borne organisms capable of causing 
meningitis.  An additional infant with bacterial meningitis was also missed.  Thus 
regardless of the laboratory parameters used, it is quite clear that no existing clinical 
criteria can confidently identify young febrile infants at low-risk for bacterial meningitis 
or, for that matter, any serious bacterial disease. 
Evidence to this notion of a disappointing inability of current guidelines to 
facilitate the diagnosis of bacteremia, meningitis, or any other serious condition for 
febrile infants was provided by a recent large prospective study.  Pantell et al. 
demonstrated that pediatricians in the United States more often than not utilized 
individual clinical judgment in the management of fever in this age group.21  Of 1746 
infants analyzed, these physicians correctly identified and treated bacteremia and 
bacterial meningitis as often as those who followed a “blended” version of current 
guidelines.  These practitioners also utilized laboratory tests (UA and peripheral WBC) 
somewhat more efficiently and hospitalized fewer patients.  Clear specificity values could 
not be presented by the authors for either approaches, but was concluded to have 
similarly suffered at the expense of greater sensitivity.  This translates into a high rate of 
false positive diagnoses.  Consequently, many infants with self-limited illnesses were 
subjected to excessive testing and treatment regardless of whether the responsible 
clinician followed current guidelines or evaluated febrile infants on an individual basis.  
That the particular tests utilized by physicians and the various clinical protocols lack 
simultaneously good sensitivity and specificity was no doubt in part to blame. 
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Of the currently available tools for the identification for bacteremia, meningitis, 
or other SBI, none has been found to be an adequately sensitive or specific indicator by 
itself.  One such test most often obtained by physicians is the peripheral WBC.  Recent 
research have clearly demonstrated that at no cutoff value does a peripheral WBC 
simultaneously have good sensitivity and specificity in infants younger than 90 days 
old.22  This corroborates well with other studies involving a larger age range of 
children.23-25  Fortunately, the value of the peripheral WBC increases once combined with 
other laboratory tests.  For example, neither peripheral WBC nor UA in the Bachur et al. 
algorithm is a particular good predictor of SBI alone.22  Combination of the two measures 
along with temperature and age improved sensitivity and specificity significantly.  A 
similar result was obtained by Pantell et al.21   
The above discussion have shown, that in spite of this incorporation of different 
laboratory parameters into various clinical criteria, these screening protocols still result in 
imprecise identification of serious infection febrile infants. Continued search for a more 
accurate indicator of SBI in young febrile infants to accompany or replace existing tests 
is therefore all the more justified in order to guide diagnostic assessment better.  This is 
especially true in the diagnosis of meningitis, where lumbar puncture is the sole means by 
which it can be diagnosed. 
 Recent advances in molecular and imaging techniques have not replaced lumbar 
puncture as the procedure of choice to diagnose meningitis in young children.26, 27  While 
CSF protein levels and pleocytosis can be highly suggestive of meningitis by themselves, 
Gram stain and culture of organisms in CSF is understandably the most reliable method 
to confirm bacterial or viral meningitis in young febrile infants.  In addition, the 
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sensitivity of CSF Gram staining for bacteria ranges greatly from 25% to 97%, depending 
upon the number of colony-forming units.7  Culture of CSF is also a time-consuming 
endeavor and is of little utility in the emergency setting.  Lumbar puncture, however, is 
notoriously difficult to perform in young infants and has a failure rate of 5%.28, 29  More 
important, concerns over the potential hazards of performing lumbar puncture have 
rightly or wrongly limited its use by physicians.29   
A major contraindication to lumbar puncture is any sign of increased intracranial 
pressure (ICP), 26, 28 such as mental status change, focal neurological deficits, and 
papilledema.  Profound elevations in ICP may result in cerebral herniation, although this 
is a rare complication.30, 31  Moreover, there is question in the current literature as to 
whether or not lumbar puncture can directly result in herniation in this setting.31, 32  
Unfortunately, computed tomography cannot reliably detect an elevation of ICP or 
cerebral herniation in children or adults.32, 33  Although there is little doubt regarding the 
value of lumbar puncture in the diagnosis of uncomplicated meningitis, clinical scenarios 
often exist in which this procedure is contraindicated. All this raises a critical question for 
physicians and researchers alike: Is there a blood test that can serve as a reasonable 
alternative to lumbar puncture to indicate the presence of meningitis? 
 Besides the peripheral WBC, at least two serum markers have been studied for 
their usefulness as indicators for SBI in febrile infants.34  The first marker is C-reactive 
protein (CRP), an acute phase reactant known to be produced by hepatocytes within 
hours of tissue injury or inflammation.  Studies by Pulliam et al.23 and Galetto-Lacour et 
al.25 both demonstrated CRP fared better than peripheral WBC as an indicator of SBI and 
may have promise as a marker.  Neither study, however, specifically recruited the young 
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febrile infants younger than 3 months.  More important, it is not possible to extrapolate 
the value of CRP as an indicator of meningitis given that no cases occurred within their 
patient population.  The second such marker is procalcitonin (PCT).  PCT rises more 
rapidly in response to infection than either WBC or CRP, although the function of this 
protein is not entirely clear and may include a role in sustaining inflammatory reactions.  
Interest in PCT stems from its previously shown dramatic increase in children afflicted 
with SBI compared to those with viral infections.35  Current literature suggest that PCT 
overall has somewhat superior sensitivity and specificity when compared to both 
peripheral WBC and CRP as an indicator in cases of SBI, including several patients with 
bacterial meningitis.24, 25, 36  Thus, these investigations has thus far suggested a potential 
role for CRP and PCT as serum markers for serious infections in young infants. To date, 
the use of CRP and PCT has not been specifically investigated for usefulness as a marker 
for meningitis in young infants.    
Nonetheless, as meningitis is a disease of the central nervous system (CNS), the 
ideal indicator of this condition would logically be an exclusive product or component of 
the CNS that becomes elevated in the bloodstream only on occasions of infections, such 
as meningitis.  Venipuncture would then become akin to an indirect sampling of the CNS, 
thus sparing young infants and their parents of the stress and pain of lumbar puncture.  
Because both are synthesized by hepatocytes, it is clear that neither CRP nor PCT would 
fit this description.   
 One potential protein that may serve as a surrogate marker of CNS inflammation 
is S-100B. First described in 1965 by a group searching for brain specific proteins,37 S-
100B is a 21-kDa calcium-binding dimeric protein found to be stable in serum for a 
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minimum of 7 months and also at -80°C.  Its name derives from its solubility in 100% 
ammonium sulphate.  S-100B is predominantly produced in high concentrations by nerve 
tissue, including astrocytes, oligodendrocytes, and Schwann cells, with at least 80-90 
percent of the total S-100B pool found in the brain.38, 39  Its gene is located on 
chromosome 21q22.3, and thus has been found to be excessively expressed in Down 
syndrome.40  S-100B functions both extracellularly and intracellularly.  Inside the cell, it 
is believed to play a role in signal transduction via the inhibition of protein 
phosphorylation and the maintenance of calcium homeostasis through cytosolic 
buffering.39   But it is its effect once secreted that is of particular interest.  Nanomolar 
concentration of extracellular S-100B has been found to be neurotrophic, favoring 
neuronal survival, whereas at micromolar concentrations, S-100B stimulates neuronal 
death via regulation of genes responsible for apoptosis and through an increase in 
calcium influx.38, 41   In addition, secreted S-100B appears to stimulate the expression of 
inducible nitric oxide synthase by astrocytes and microglia; subsequent nitric oxide 
diffusion has led to co-cultured neuronal cell death.42, 43  Expression of interleukin-6 (IL-
6), a proinflammatory cytokine, by neurons is also elevated due to S-100B activity.44  
These functions of S-100B have led to its implication in the pathogenesis of neurological 
diseases in which inflammation may play a role, such as Alzheimer’s,45 or disorders 
characterized by the improper maturation of neurons, such as cerebral palsy and delayed 
development.46 
S-100B has been postulated to be an important component of the infectious 
diseases of the CNS. Cerebrospinal fluid levels of  S-100B have previously been found to 
be elevated in young infants (median age = 9 days) with bacterial meningitis.47  In this 
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study, CSF S-100B levels also correlated well with CSF WBC and protein levels and 
inversely correlated with glucose concentrations in infants with meningitis.  Another 
study of CSF S-100B involving older children with either aseptic or bacterial meningitis 
had significantly elevated CSF S-100B concentrations whereas those with alternative 
diagnoses did not.  However, a statistical difference in CSF levels of S100B was not 
found between those children with aseptic and bacterial meningitis.48  Thus, these studies 
suggest CSF S-100B may be a useful marker for meningitis of any etiology in the 
pediatric population, including very young infants. 
A natural extension of these investigations is whether or not serum S-100B 
concentrations can serve as a marker of CNS infection, especially meningitis. Normally, 
serum S-100B concentrations do not differ with gender and are simply inversely 
correlated with age.  Levels are greatest in healthy neonates less than 48 hours of age and 
progressively decrease until stabilizing after age 20 years.49, 50  This age disparity may 
reflect neurodevelopmental processes.  Of note, Lins et al. of Germany recently 
examined the potential of serum S-100B as a marker for meningitis.51  Their investigation 
of 32 consecutively-admitted adults with laboratory confirmed infection of the CNS 
(bacterial or viral meningitis/ meningoencephalitis or neuroborreliosis) demonstrated that 
both CSF and serum S-100B levels drawn on admission were significantly elevated 
above controls with non-infectious CNS conditions, such as psychosomatic disorders or 
headaches.  Moreover, initial S-100B concentrations in both serum and CSF could be 
used to distinguish bacterial CNS infection from viral meningitis/ meningoencephalitis 
and neuroborreliosis.  A distinct correlation was also found between S-100B and standard 
CSF parameters for CNS infection, including pleocytosis.   
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Hypothesis 
Based on this information, we hypothesize that serum S-100B levels in young 
febrile infants with meningitis will be significantly greater than those febrile infants 
without CNS infection. 
 
Purpose 
The aim of this study is to assess the potential of serum S-100B as an indicator of 
infantile meningitis of any etiology and ultimately to facilitate the diagnosis of this 




Study design.  This was a prospective, cohort study conducted at the pediatric 
emergency department at the Yale-New Haven Children’s Hospital, New Haven, 
Connecticut between April 2006 and September 2007.  Our emergency department sees 
approximately 31,000 visits annually, of which about 200 are evaluations for sepsis in 
young infants that require lumbar puncture and venipuncture.  The study protocol was 
reviewed and approved by the Yale University School of Medicine Human Investigation 
Committee prior to patient recruitment. 
 
Study Population.  The study attempted to enroll all eligible children between the ages 
of 1 day and 90 days old who presented to the emergency department and was deemed by 
the responsible physician to require venipuncture, lumbar puncture, and bladder 
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catheterization as part of their diagnostic work-up due to the presence of a fever or a 
history or clinical appearance that was worrisome for meningitis.  Fever was defined as 
either a confirmed rectal temperature ≥38.0ºC in the emergency department or a history 
of a rectal temperature ≥38.0ºC. Informed, written consent was acquired by a physician 
from all parents or legal guardians of the eligible infants before inclusion of the subject 
into the study.  Exclusion criteria for study subjects was set as the following: 1) no 
requirement for lumbar puncture; 2) no requirement for blood tests; 3) inability to obtain 
blood sample; 4) inability to obtain CSF sample; 5) history of recent seizure; 6) history of 
recent head trauma; 7) history of neurodegenerative disease; 8) history of gestational age 
less than 36 weeks; and 9) history of intraventricular hemorrhage. 
 
Study Definitions.  The definition of meningitis in this study was necessarily broad in 
recognition of the difficulties associated with lumbar punctures that often results in an 
inadequate volume of CSF for all analyses and/or the presence of a traumatic lumbar 
puncture that complicates the interpretation of the actual WBC count in the CSF.  A 
subject is thus deemed to have meningitis if any of the following criteria are met: 1) 
positive CSF bacterial or viral culture or positive PCR for either enterovirus or herpes 
simplex virus ; 2) CSF pleocytosis in the absence of hemorrhage; or 3) a CSF white-
blood-cell to red-blood-cell ratio (WBC:RBC) is >1/100.52   CSF pleocytosis is defined 
as >15 cells/μL based on previous reports that WBC counts greater than this would have 
a high sensitivity for identifying children with bacterial meningitis.1, 22-25  A traumatic 
lumbar puncture is defined as the presence of >500 red blood cells/ μL.52, 53   
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Study groups.  Febrile infants were distributed into two groups according to presence or 
absence of meningitis.  Patients with meningitis were defined as per above.  Febrile 
infants without laboratory documentation of infection in their CSF made up the control 
group.  Laboratory technicians performing the subsequent serum analysis for S-100B 
were blinded to the patient's final diagnosis based on CSF laboratory studies. 
 
Sample procurement.  Urine, CSF, and blood samples were obtained from all study 
patients as part of their evaluation for bacterial sepsis.  Bladder catheterization via 
suprapubic or urethral techniques was used to yield urine samples for culture and 
urinalysis.  Lumbar puncture was performed as per usual protocol, and the subsequent 
CSF was analyzed for cell count, protein, and glucose concentrations and cultures for 
bacteria and viruses.  PCR for enterovirus and herpes virus was used to replace the viral 
culture in the event of a hemorrhagic tap.  
Blood samples were obtained by standard venipuncture technique for the routine 
testing (complete blood count, culture) ordered by the treating physician.  An additional 
1.0 mL of blood for S-100B testing was also obtained at the initial venipuncture, but only 
after all necessary blood samples needed for treatment had been acquired.  No additional 
venipuncture attempts were made to obtain a blood sample for the sole purpose of this 
study if a blood sample could not be gathered with the necessary laboratory tests for the 
evaluation of the patient’s fever.  The 1.0 mL samples of blood were then centrifuged 
within 8 hours of venipuncture to yield serum.  All serum samples were then 
subsequently frozen and stored until processing at the end of patient enrollment period. 
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Serum S-100B levels for each subject were determined by the Can Ag S-100B 
assay, an enzyme linked immunoassay (ELISA).  Samples were thawed to room 
temperature.  Wash buffer and standard and control reagents were reconstituted with 
deionized water.  Fifty µL of each standard and control reagent were combined with 50 
µL of serum sample.  A volume of tracer equal to that of the latter mixture was added 
prior to an incubation period of 2 hours.  After washing the unbound tracer and residual 
antibodies off with wash buffer, samples were then incubated once more for 15 minutes 
on a plate shaker at 800 RPM with 100 µL of TMB substrate.  One hundred µL of TMB 
stop solution was utilized to halt the reaction, and the absorbance of each sample was 
read over a 15 minute period at 450 nm using a microplate reader.  To minimize 
laboratory drift, control and case samples were analyzed in batches. 
 
Statistical analysis.  A previous study observed that the median serum S-100B levels in 
19 healthy neonates is 1790 ng/L (interquartile range = 1570-2440) and 365 ng/L (267-
410) in children between the ages of 4 and 9 years.49  This yielded an estimated standard 
deviation of 960 and 140 ng/L in neonates and children, respectively.  As the variability 
and central tendency of serum S-100B is not yet available, we utilized the most 
conservative (neonatal) estimate of standard deviation as a point of reference and 
postulated that a sample size of 130 subjects with meningitis and 130 without meningitis 
would provide a power of 80% to detect differences of 390 ng/L and a two-sided 
significance level of 0.016.   
 For this interim analysis, power calculations were repeated based on the sample 
recruited and a two-sided significance level of 0.05.  Serum S-100B levels were reported 
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as medians and interquartile ranges.  Comparison of serum S-100B levels between groups 
were performed using the Wilcoxon rank sum test.  A non-parametric receiver operating 
characteristic (ROC) curve was generated for serum S-100B to evaluate its potential as a 
diagnostic test for meningitis.  We examined for any potential relationship between 
discrete variables, such as gender and race, and the diagnosis of meningitis using the 
Pearson Χ2 test or the Fisher exact test as necessary for situations with smaller sample 
sizes.  A two-sided alpha level of 0.05 is considered to be significant.  All statistical 
analyses were conducted with Stata/IC 10 (College Station, TX).  
 
Results 
A total of 111 eligible infants had been recruited by the end point date for this 
interim analysis, which was 18 months into the projected 3-year enrollment period.  
Several eligible patients were not included in this study predominantly due to guardian 
refusal or inadequate blood sampling.  Prevalence of meningitis between participants and 
non-participants did not differ.  Insufficient serum volume for analysis is also the reason 
for the unavailability of serum S-100B levels for 10 (9%) of the 111 participants.  
Meningitis occurred in 27 (26.7%) of the 101 infants with S-100B levels available 
compared to 2 (20%) of the 10 who did not (Χ2df=1=0.21, p=0.64).  Three of the 27 cases 
of meningitis were apparently bacterial in etiology, 2 of which were identified as 
coagulase-negatvie Staphylococcus.  No organisms were initially seen in any of these 3 
suspected bacterial cases on Gram stain of the CSF.  One of the 3 cases was 
simultaneously found to be positive by PCR for enteroviral infection of the CNS.  In the 
non-meningitis group, the vast majority (57%) did not have a confirmed etiology for their 
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fever.  Septicemia was, however, identified in 10 (13.5%) infants, urinary tract infections 
in 12 (16.2%), and respiratory tract infections, including pneumonia, in 13 (17.5%).  
Some of these patients had multiple possible etiologies as the source for fever. 
Ad hoc power calculations based on our effective sample size of 101 and the 
approximately 1-to-3 ratio of case versus control suggested that this interim analysis only 
had a 57% probability of detecting a difference of 390 ng/L between the two groups.   
Table A shows the demographics of those with and without meningitis.  
Overlapping 95 percent confidence intervals suggest that the mean age of the two groups 
did not differ.  Neither male gender (Χ2df=1=1.49, p=0.22) nor Caucasian race 
(Χ2df=1=0.27, p=0.60) was associated with the diagnosis of meningitis.  In an attempt to 
characterize the clinical presentation of the infants, information regarding the number of 
hours the child had already been afflicted with fever by the time of presentation to the 
emergency department was also collected.  We realize, however, that the subjective 
nature of this data limits its reliability and therefore is not presented here.  Similarly, an 
analysis of the various laboratory values, such as WBC count, between the two diagnostic 
groups is omitted due to their inadequate utility as measures of clinical severity in this 
age population.34 
Table A. Demographics of subjects with meningitis (n=27) and without meningitis (n=74). 
 + Meningitis 
# (95% CI) 
# (%) 
- Meningitis 
# (95% CI) 
# (%) 
Age (weeks) 5.45 (4.67, 6.23) 4.84 (4.28, 5.40) 
Male 19 (65.5%) 43 (52.4%) 
Caucasian 14 (48.3%) 35 (42.7%) 
No differences exist between the age at presentation to the emergency department and the diagnosis of 
meningitis.  No relationship exists between male gender or Caucasian race and the diagnosis of meningitis. 
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Figure 1 provides a box plot representation of the distribution of serum S-100B 
levels in the infants with (+) and without (-) meningitis.  The 25th- and 75th- quartiles, as 
marked by the leftmost and rightmost boundaries of the boxes, appear similar between 
the groups.  The median S-100B level (red line) for the meningitis group is 247.0 ng/L 
(103.5, 804), while that for the non-meningitis group is 199.1 ng/L (142.5, 384.0).  No 
significant difference exists between these two values (p>0.05). 
 
Figure 1. Box plot of serum S-100B (ng/L) distribution in infants 0-3 months of age with meningitis (+) 
and without meningitis (-). 





The serum S-100B distribution between the two groups is nearly identical.  The boxes mark the 
interquartile ranges with the median indicated by the red line.  The lower and upper bars represent the 5th 
and the 95th percentiles.  An outlying value is shown by the diamond. 
 
 In addition, we utilized ROC curve analysis to evaluate the value of serum S-
100B as a diagnostic test for meningitis.  As figure 2 demonstrates, the curve nearly 




0.4917 (0.3940, 0.5863).  Thus, no value of serum S-100B had an acceptable 
combination of sensitivity and specificity. 
 
Figure 2. Receiver operating characteristic (ROC) curve of serum S-100B as diagnostic test for meningitis 
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The sensitivity of serum S-100B for meningitis is plotted along the y-axis against its false positive rate (1-
specificity) along the x-axis.  The ROC curve follows the 45-degree reference line and the area under the 
ROC curve approximates 0.5, therefore indicating no significance. 
 
Discussion 
 In this interim analysis, we found no difference in the serum S-100B levels of 
infants with meningitis and without meningitis.  This is hardly surprising, as the sample 
size is less than half of the amount deemed a priori to be necessary to have sufficient 
power.  This is confirmed by the ad hoc power calculation, which found the ability for 
this study to detect a meaningful difference in S-100B levels between the two groups to 
be only 57 percent.  As a result, at this time, little can be said about the utility serum S-
100B has as a biomarker for meningitis in infants.  Any conclusions based on an 
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insufficiently powered analysis would be premature; Hennekens and Buring went as far 
to remark that to do so would have the potential to cause “great scientific harm.”54  In this 
case, a hasty conclusion of a null result may discourage continuation of this study, which 
given a full enrollment may reliably reject the null hypothesis instead.  Because 
meningitis will remain a sought-after cause of fever in young infants, an alternative to the 
current gold standard of CSF analysis for the diagnosis of meningitis will continue to be 
necessary.  The inconclusiveness of this interim analysis still leaves serum S-100B as a 
logical option for investigation. 
 Our review of current relevant literature suggests two general mechanisms by 
which S-100B could become serum marker for meningitis in very young children.  The 
first relates to its presence in the CNS of healthy individuals, especially the relatively 
high levels of serum S-100B in term neonates.49  S-100B is found predominantly within 
the cytosol of astrocytes within the CNS, where the concentration can be as high as 10 
μL.39, 55, 56  In the setting of the cell damage that is known to occur in acute meningitis, it 
is possible that the intracellular pool of S-100B is thereby first released into the CSF and 
finally through the blood-brain barrier to the peripheral bloodstreams.57  The blood brain 
barrier has been found to become more permeable with the abundant release of cytokines, 
such as tumor necrosis factor α (TNF- α), which no doubt occurs during an acute 
infection.58  The may be reflected by prior reports of elevated CSF and serum S-100 in 
not only meningitis itself,47, 51 but also after traumatic brain injuries59, 60 and hypoxic60-62 
strokes, where direct damage to astrocytes likely have occurred.  Gazzolo et al. also 
found rising levels of S-100B in the urine of preterm infants with intraventricular 
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hemorrhage, although it should be noted that a nervous versus renal origin of this S-100B 
must be considered given the possibility of metabolization prior to renal filtration.63, 64 
A rise in S-100B in the peripheral bloodstream secondary due to direct glial cell 
damage, however, is likely an over-simplification because it limits S-100B to a bystander 
role, in which it is an effect, rather than a part, of the disease process.  In light of studies 
that have associated S-100B with several CNS-related conditions in which inflammation 
is also a significant part of their pathogenesis, a more active role for S-100B must be 
considered.  In multiple sclerosis for instance, Massaro et al. and Missler et al. has 
respectively observed an increase in CSF (n=10) and plasma (n=7) S-100B during the 
acute phase of disease exacerbation.65, 66  Similarly, Mokuno et al. noted greater levels 
and a longer duration of elevation of CSF S-100B in 16 of 24 Guillain-Barré patients who 
had an extended recovery course compared to the remaining 8 patients with lower CSF S-
100B levels and a shorter recovery.67  These studies, combined with current molecular 
data, suggest secreted S-100B has the potential to initiate or intensify the cytokine 
cascade of the inflammatory response seen in these diseases and meningitis. 
Van Eldik and Zimmer first described the secretion of S-100B in an animal 
model.68  While the means by which this is accomplished remains unclear, one important 
early proinflammatory cytokine in bacterial meningitis, interleukin-1(β) (IL-1 or IL-1β), 
has been reported to be stimulate astrocytes to release S-100B.39  The beginning of our 
hypothetical pathway may thus consist of the activation of monocytes, macrophages, 
granulocytes, endothelial cells, microglial cells, and astrocytes within the CNS by various 
cell wall components or toxins of pathogens to release IL-1.57  In turn, an overwhelming 
stimulation of IL-1 would then induce, among many chemical mediators in the 
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inflammatory cascade, the secretion of S-100B at non-physiological (micromolar) 
amounts by astrocytes.  Excessive extracellular S-100B exerts its paracrine effect likely 
at least partly via the chronic engagement of the multiligand, transmembrane receptor for 
advanced glycation end products (RAGE) on neurons and microglia.  This results in 
nuclear translocation and the activation of transcription factors, Sp1 and NFκB, in 
microglia and, Sp1, in cortical neurons, which ultimately leads to the formation of even 
more IL-1β.69-71  Previous data that show a correlation between CSF IL-1β levels and the 
severity of disease in patients with acute bacterial meningitis would be consistent with 
this proposed mechanism.72 
S-100B also exerts an autocrine effect on astrocytes via RAGE that further adds 
to cytokine cascade.  More specifically, Ponath et al. demonstrated that S-100B 
upregulated interleukin-6 (IL-6) and TNF- α in a RAGE-dependent manner.  Both 
cytokines are known to be markedly elevated in the acute bacterial meningitis.57 As 
mentioned above, the permeability of the blood-brain barrier increases significantly 
because of the action of cytokines.  S-100B would thus be able contribute to its own 
presence in the periphery during acute meningitis.   
Of course, this interim analysis could not with any confidence comment on the 
plausibility of either of the aforementioned mechanisms by which serum S-100B could 
become a biomarker for meningitis.  Nonetheless, even if a difference in the levels of 
serum S-100B were to be detected at the conclusion of patient recruitment, interpretation 
must still proceed with caution.  Limitations exist regardless of our attempts to minimize 
the number via the study’s design.  Selection bias may occur due to the broad inclusion 
criteria as guardians of infants who are seemingly less ill may be less inclined to 
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participate.  Thus far, however, the frequency of aseptic and bacterial meningitis is nearly 
the same between participants and the few non-participants.  Another source of selection 
bias lies in the decision to perform a full diagnostic work-up on non-febrile infants whose 
clinical manifestation may or may not be worrisome to the particular physician 
responsible.  Interrater agreement is therefore also of concern for those few patients 
enrolled through this route.  Observation bias in the form of recall bias or loss of subjects 
to follow-up is fortunately unlikely in this study, as the outcome of interest is objective in 
nature and patient involvement is limited to the initial venipuncture, respectively.  In 
contrast, the realities of clinical medicine do make misclassification possible.  The sheer 
difficulty of performing an atraumatic or a volume-sufficient lumbar puncture has, to date, 
limited the number of subjects with CSF that is uncontaminated by hemorrhage and 
confirmed for infection via positive viral cultures.  We, therefore, must rely upon the 
less-than-ideal combinationof viral and bacterial cultures, viral PCR, the presence of 
pleocytosis, and/ or CSF WBC to CSF RBC ratio to establish the diagnosis of meningitis.  
Finally, there always exist the possibility that an excessively traumatic venipuncture may 
elicit sufficient extracerebral S-100B to contaminate the serum sample.73, 74  Thus far 
though, most of our venipunctures with our subjects have been uncomplicated.  This may 
help keep the chance of this complication arising low. 
In summary, serum S-100B does not appear to be a useful biomarker for 
meningitis at this time.  If the result of this interim analysis were to continue to hold true, 
there are at least two explanations to account for this.  First and foremost, the low 
cumulative incidence of bacterial meningitis in the vaccination era limits the cases to 
those secondary to viruses.  This low incidence is reflected by our sample, in which only 
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3 cases of bacterial meningitis were found.  These were, however, dubious, as 2 were 
apparently due to coagulase-negative Staphylococcus and none had visible organisms on 
Gram staining.  The relatively mild nature of viral meningitis is epitomized by its more-
often-than-not spontaneous resolution and limited long-term sequelae.  When compared 
to bacterial cases, the extent of the inflammatory response and damage to CNS would be 
expected to be curtailed in viral cases.  The release of S-100B into the periphery would 
thereby be minimized.  While we are not aware of any reports in the literature of this, 
another possibility is that S-100B from corporeal sources may be elevated in the serum 
due to the hyperpyrexia itself through an unknown mechanism.  This may be significant 
enough to obscure any additional serum S-100B derived from the CNS.  Other potential 
reasons include those relating to the timing of venipuncture, our laboratory technique, 
and the power to detect a truly meaningful difference in serum S-100B levels. 
The latter problem currently hinders our ability to draw a conclusion based on this 
interim analysis.  Unfortunately, even our power calculations a priori relied upon 
estimates from a limited number of human subjects not derived from our region.  
Moreover, the calculated sample size for adequate power assumes a one-to-one ratio of 
cases and controls in order to limit the number of participants required.  This no doubt is 
somewhat unrealistic with increasing immunizations against H. influenza type B and 
Streptococcus pneumoniae.  Patient enrollment period therefore will likely increase 
beyond the stated three year time frame, and questions may be raised as to the 
comparability of patients at different points of recruitment.  The importance of 
discovering a diagnostic test that can distinguish infants at risk for meningitis, however, 
continue to remain indisputable. 
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